NOTE 8 - EQUITY TRANSACTIONS	12 Months Ended
Dec. 31, 2019
Notes
NOTE 8 - EQUITY TRANSACTIONS	NOTE 8 – EQUITY TRANSACTIONS On February 20, 2018, the Company filed a designation statement with the State of Nevada designating the 2017 Series A Preferred Stock, authorized December 12, 2017, consisting of 12,500,000 shares of the Company’s previously authorized but unissued shares of Preferred Stock. The designation statement was withdrawn the next day. The authorization and issuance of the 10,700,000 shares of the Company’s Series A Preferred Stock which was previously reported in a Form 8-K dated December 12, 2017, was withdrawn. As a result, $107,000 in shareholder loans that were cancelled in exchange for the issuance of the Series A Preferred Stock were reinstated at December 31, 2017. On March 9, 2018, the Company repurchased 105,000,000 shares of its outstanding common stock (the “Control Shares”) held by Bradly Petersen (“Mr. Petersen”), for cash of $10,000. As a result of this transaction, Mr. Petersen no longer holds any interest in the Company, and the Control shares have been cancelled so that there are 11,000,000 issued and outstanding shares of Common Stock at December 31, 2019 and 2018. BIOETHICS, LTD. NOTES TO FINANCIAL STATEMENTS December 31, 2019 On December 2, 2019, the Company amended its articles of incorporation with the State of Nevada increasing the number of authorized common stock of the Company to 250,000,000 shares.

NOTE 8 - EQUITY TRANSACTIONS

12 Months Ended

Dec. 31, 2019

NOTE 8 – EQUITY TRANSACTIONS

On February 20, 2018, the Company filed a designation statement with the State of Nevada designating the 2017 Series A Preferred Stock, authorized December 12, 2017, consisting of 12,500,000 shares of the Company’s previously authorized but unissued shares of Preferred Stock. The designation statement was withdrawn the next day. The authorization and issuance of the 10,700,000 shares of the Company’s Series A Preferred Stock which was previously reported in a Form 8-K dated December 12, 2017, was withdrawn. As a result, $107,000 in shareholder loans that were cancelled in exchange for the issuance of the Series A Preferred Stock were reinstated at December 31, 2017.

On March 9, 2018, the Company repurchased 105,000,000 shares of its outstanding common stock (the “Control Shares”) held by Bradly Petersen (“Mr. Petersen”), for cash of $10,000. As a result of this transaction, Mr. Petersen no longer holds any interest in the Company, and the Control shares have been cancelled so that there are 11,000,000 issued and outstanding shares of Common Stock at December 31, 2019 and 2018.

BIOETHICS, LTD.

NOTES TO FINANCIAL STATEMENTS

December 31, 2019

On December 2, 2019, the Company amended its articles of incorporation with the State of Nevada increasing the number of authorized common stock of the Company to 250,000,000 shares.